Key Highlights

● Oncolytics furnished a press release on a PNAS paper about pelareorep in hepatocellular carcinoma, published September 28, 2026.

● The release calls the work preclinical and says pelareorep can turn immunologically cold tumors into hot ones open to immunotherapy.

● Listed changes include higher PD-L1 expression, increased ICOSL on tumor cells, greater CD8 T cell density and tertiary lymphoid structures.

● Chief Medical Officer Thomas Heineman said liver cancer is not an indication the company intends to pursue at this time.

Oncolytics Biotech Inc. (NASDAQ:ONCY) used a Form 8-K filed on September 29, 2026 to furnish a press release about a newly published scientific paper on its investigational immunotherapy, pelareorep. The release, datelined San Diego, is headlined "Oncolytics Biotech Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy." The filing was made under Item 8.01, Other Events, and the press release is attached as Exhibit 99.1.

What the Publication Reports

The paper is titled "MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma" and appeared in the Proceedings of the National Academy of Sciences, or PNAS, with a publication date of September 28, 2026. The press release describes the work as preclinical research, meaning it does not report results from patients treated with pelareorep for liver cancer. It does not list the paper's authors, and it does not give sample sizes or statistical results.

The central finding, as the company describes it, is that pelareorep can convert immunologically inactive tumors, which the release calls cold, into immunologically active ones, called hot, that are susceptible to immune-based therapy. In hepatocellular carcinoma, the release says the tumor microenvironment shifted from suppressive to permissive for immune-mediated destruction of tumor cells. The specific changes the release lists are increases in PD-L1 expression, higher levels of ICOSL on tumor cells, greater density of CD8 T cells, the formation of tertiary lymphoid structures, and enhanced PD-1/PD-L1 signaling and ICOSL-mediated communication.

The Company's Comments

The release quotes Thomas Heineman, MD, PhD, Oncolytics' Chief Medical Officer. He says the publication provides additional evidence that pelareorep alters the tumor microenvironment in traditionally challenging indications, and he links that ability to the company's Business development conversations. He also states that "liver cancer is not an indication we intend to pursue at this time," adding that the data align with the company's view that pelareorep works in challenging tumor types and can be considered a backbone immunotherapy that can improve the activity of many cancer treatments while maintaining a favorable safety profile.

The company is presenting the paper as supporting evidence for pelareorep's mechanism of action, not as the start of a liver cancer program. The release does not announce a clinical trial, a regulatory submission or any financial terms.

Background on Pelareorep

The release describes pelareorep as an intravenously delivered investigational immunotherapy with a dual mechanism of action: it selectively replicates in tumor cells and activates innate and adaptive anti-tumor immune responses. It says the therapy has been administered to more than 1,200 patients across multiple studies, and it cites encouraging outcomes in first-line pancreatic cancer studies, positive results in two randomized Phase 2 metastatic breast cancer studies, and early-phase activity in anal and colorectal cancer. The company says pelareorep holds Fast Track Designation from the U.S. Food and Drug Administration for colorectal, anal and pancreatic cancers, and that its development focus is combinations with chemotherapy and, or, checkpoint inhibitors in metastatic gastrointestinal cancers.

Oncolytics describes itself as a clinical-stage biotechnology company that actively pursues strategic partnerships to accelerate development and maximize commercial potential.

Securities Exchange Act of 1934 and Canadian securities laws.

Pelareorep PNAS Paper and Liver Cancer Stance

The filing sets no dates. Because the company says liver cancer is not an indication it intends to pursue now, further developments described in the release center on its gastrointestinal cancer programs and its business development discussions, and any agreements would need to be announced separately by the company.